Study of SMT-NK Inj. Plus Pembrolizumab vs Pembrolizumab Monotherapy in Patients With Advanced Biliary Tract Cancer

Phase 2/3 Unknown 128 enrolled SMT bio Co., Ltd.

RandomizedParallel-groupOpen-labelTreatment

Summary

This study is designed to assess the antitumor activity of combination therapy of SMT-NK (allogeneic natural killer cells) and pembrolizumab versus pembrolizumab monotherapy in patients with advanced biliary tract cancer

Timeline

Start: 2022-06-09
Primary completion: 2025-01-08
Completion: 2026-06-08

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Pembrolizumab	Monoclonal antibody	200 mg	Intravenous
Subject	SMT-NK	Cell therapy	3e+06 cells/kg	Intravenous

Study of SMT-NK Inj. Plus Pembrolizumab vs Pembrolizumab Monotherapy in Patients With Advanced Biliary Tract Cancer

Summary

Timeline

Drugs

Indications